Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma

Annals of the American Thoracic Society

Volumn 10, Issue SUPPL, 2013, Pages

  Arron, Joseph R ^a   Choy, David F ^a   Scheerens, Heleen ^a   Matthews, John G ^a  

^a GENENTECH INC   (United States)

Author keywords

Eosinophil; Fractional exhaled nitric oxide; IgE; IL 13; Periostin

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 5; LEBRIKIZUMAB; MEPOLIZUMAB; NITRIC OXIDE; PITRAKINRA; TRALOKINUMAB;

ASTHMA; BIOLOGICAL THERAPY; EOSINOPHIL COUNT; EOSINOPHILIA; GENE EXPRESSION; HUMAN; INFLAMMATION; PHARMACODYNAMICS; REVIEW;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BIOLOGICAL MARKERS; BREATH TESTS; CELL ADHESION MOLECULES; DRUG DISCOVERY; EOSINOPHILS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-4; LEUKOCYTE COUNT; NITRIC OXIDE; TREATMENT OUTCOME;

EID: 84892490403     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201303-047AW     Document Type: Review

References (50)

1. McClintock D, Corren J, Hanania NA, Mosesova S, Lal P, Arron JR, Eisner MD, Matthews JG. Lebrikizumab, an anti-IL-13 monoclonal antibody, reduces severe asthma exacerbations over 32 weeks in adults with inadequately controlled asthma. Am J Respir Crit Care Med 2012;185:A3959.
2. Scheerens H, Arron JR, Choy DF, Mosesova S, Lal P, Matthews JG. Lebrikizumab treatment reduces serum periostin levels in asthma patients with elevated baseline levels of periostin. Am J Respir Crit Care Med 2012;185:A3960.
3. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009;8:959 -968.
4. Arron JR, Scheerens H, Matthews JG. Redefining approaches to asthma: developing targeted biologic therapies. Adv Pharmacol 2013;66:1-49.
5. Blakey JD, Wardlaw AJ. What is severe asthma? Clin Exp Allergy 2012; 42:617-624.
6. Hashimoto S, Bel EH. Current treatment of severe asthma. Clin Exp Allergy 2012;42:693 -705.
7. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol 2011;128: 1165-1174.
8. Braman SS. The global burden of asthma. Chest 2006; 130:4S-12S.
9. Catley MC, Coote J, Bari M, Tomlinson KL. Monoclonal antibodies for the treatment of asthma. Pharmacol Ther 2011;132:333-351.
10. Holgate ST. Trials and tribulations in identifying new biologic treatments for asthma. Trends Immunol 2012;33:238-246.
11. Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 2012;11:958-972.
12. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-178.
13. Pulendran B, Artis D. New paradigms in type 2 immunity. Science 2012;337:431-435.
14. Belda J, Leigh R, Parameswaran K, O'Byrne PM, Sears MR, Hargreave FE. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000;161:475-478.
15. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-879.
16. Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, Bleecker ER; National Heart, Lung, and Blood Institute Sever Asthma Research Program. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010;125:1028-1036. e13.
17. McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, Fahy JV; Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012;185:612-619.
18. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identi fication using induced sputum. Respirology 2006;11:54-61.
19. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven infl ammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388-395.
20. Choy DF, Modrek B, Abbas AR, Kummerfeld S, Clark HF, Wu LC, Fedorowicz G, Modrusan Z, Fahy JV, Woodruff PG, et al. Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. J Immunol 2011;186: 1861-1869.
21. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, Hamid Q, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647-654.e10.
22. St Ledger K, Agee SJ, Kasaian MT, Forlow SB, Durn BL, Minyard J, Lu QA, Todd J, Vesterqvist O, Burczynski ME. Analytical validation of a highly sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna immunoassay system. J Immunol Methods 2009;350:161-170.
23. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, Sidhu SS, Dao-Pick TP, Pantoja C, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007;104:15858-15863.
24. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118:3546-3556.
25. Chibana K, Trudeau JB, Mustovich AT, Hu H, Zhao J, Balzar S, Chu HW, Wenzel SE. Il-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy 2008;38:936-946.
26. Jiang J, Malavia N, Suresh V, George SC. Nitric oxide gas phase release in human small airway epithelial cells. Respir Res 2009;10:3.
27. Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006;61:817-827.
28. Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, Hunt JF, Kita H, Liu AH, Panettieri RA Jr, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012; 129:S9-S23.
29. Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, Muller SJ, Fahy JV. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 2010;107:14170-14175.
30. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-659.
31. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebocontrolled study. Am J Respir Crit Care Med 2011;184:1125-1132.
32. Molfino NA, Novak R, Silverman RA, Rowe BH, Smithline H, Khan F, Fiening JP, Kim K, Parker JM. Reduction in the number and severity of exacerbations following acute severe asthma: results of a placebo-controlled, randomized clinical trial with benralizumab. Am J Respir Crit Care Med 2012;185:A2753.
33. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, Wenzel SE, Chon Y, Dunn M, Weng HH, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181: 788-796.
34. Otulana BA, Wenzel SE, Ind PW, Bowden A, Puthukkeril S, Tomkinson A, Meyers DA, Bleecker ER, Yen YP. A phase 2b study of inhaled pitrakinra, an IL-4/IL-13 antagonist, successfully identified responder subpopulations of patients with uncontrolled asthma. Am J Respir Crit Care Med 2011;183:A6179.
35. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365: 1088-1098.
36. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013;41: 330-338.
37. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma. Am J Respir Crit Care Med 2013; 187:804-811.
38. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154:573-582.
39. Selby A, Clayton B, Grundy J, Pike K, Drew K, Raza A, Kurukulaaratchy R, Arshad SH, Roberts G. Are exhaled nitric oxide measurements using the portable NIOX MINO repeatable? Respir Res 2010;11:43.
40. Sasaki H, Dai M, Auclair D, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y, Chen LB. Serum level of the periostin, a homologue of an insect cell adhesion molecule, as a prognostic marker in nonsmall cell lung carcinomas. Cancer 2001;92:843-848.
41. Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, Chen LB, Elias A. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat 2003;77:245-252.
42. Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K, Ohshima K, Shiraishi H, Uchida M, Ono J, et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J 2011;37:1119-1127.
43. Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, Toda S, Inagaki N, Kurihara Y, Hayashida S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest 2012;122:2590-2600.
44. Kudo A. Periostin in fibrillogenesis for tissue regeneration: periostin actions inside and outside the cell. Cell Mol Life Sci 2011;68: 3201-3207.
45. Shimazaki M, Nakamura K, Kii I, Kashima T, Amizuka N, Li M, Saito M, Fukuda K, Nishiyama T, Kitajima S, et al. Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med 2008; 205:295-303.
46. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, et al.; International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062-1071.
47. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-984.
48. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-993.
49. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167: 199-204.
50. Song CH, Lee JK, Matthews JG. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:2433-2434, author reply 2433-2434.